---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-001575"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2022-02-14T23:59:59+00:00"
generated_at: "2026-06-27T08:23:07.728730+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech reports Q1 net loss of $4.4M; Health Canada approves Phase 3 design for EB05

## Summary
- Net loss $4.38M ($0.33/share) vs $2.64M ($0.26/share) a year ago; operating expenses up $2.55M.
- R&D expenses increased $2.57M to $3.95M, primarily due to external clinical study and drug product costs.
- Health Canada approved Phase 3 design of Phase 2/3 study for EB05 as rescue therapy for ARDS.
- Phase 2b chronic Allergic Contact Dermatitis study reached enrollment milestone; pace returning to pre-pandemic.
- Working capital $8.14M; cash $5.88M; subsequent equity issuance raised ~$1.19M from RBC Capital Markets.

## SEC filing metadata
- accession: 0001654954-22-001575
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2022-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000165495422001575/0001654954-22-001575-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000165495422001575/edsa_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-001575
- JSON: https://secwatch.observer/filing/0001654954-22-001575.json
- Plain text: https://secwatch.observer/filing/0001654954-22-001575.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.